Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) "COGENT-1"
Terminated
Phase 3 Results N/ASummary of Purpose
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease, in the setting of concomitant aspirin therapy. Antiplatelet therapy is an... Trial Stopped: Terminated by Sponsor
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 27 January 2009.
| 1 Dec 2007 | 12 Nov 2007 | 1 Nov 2009 | 1 Nov 2009 | 1 Jan 2009 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
-
Pablo Lapuerta, MD Phone: 650-543-4730
clinicaltrials@cogentus.net
View Trial Locations
Recruitment
- Enrollment: 5,000
- Gender: Both
- Minimum Age: 21 Years
- Accepts Healthy Volunteers: No
- 491 locations, 16 countries
Principal Investigator
- Pablo Lapuerta, MD
Cogentus Pharmaceuticals
